BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Johnson & Johnson (JNJ) Halts Tylenol Production in South Korea Over Mishap


5/3/2013 8:31:50 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Johnson & Johnson may have a new image campaign to help consumers, investors and physicians overlook the cascade of recalls and scandals (see this), but such promotional efforts are no substitute for improved manufacturing procedures. And such gaffes are still occurring. The latest is taking place in South Korea, where its Janssen unit was ordered to halt production of two types of Children's Tylenol syrup because the drugmaker violated manufacturing regulations, The Korea Times writes. The move comes one week after J&J (JNJ) recalled all 170 batches of cherry-flavored Children’s Dye-Free Tylenol Suspension because some bottles contained a higher concentration of the active ingredient - acetaminophen - than specified on the label and could, potentially, cause liver damage. And the drugmaker faces up to six months of production suspension for violating rules, according to the Ministry of Food and Drug Safety.

Help employers find you! Check out all the jobs and post your resume.


Read at PharmaLive

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES